UroGen Pharma announced strong preliminary results from its Phase 3 UTOPIA trial for UGN-103, showing a 77.8% three-month complete response rate for patients with recurrent low-grade intermediate-risk ...
Despite majoring in engineering, a Cranberry Township woman took on a health-related project when applying to graduate school ...
That was until she partook in a relatively new program offered at White Pines Collegiate and Vocational School that pumps up ...
The DESTINY-Breast11 trial showed in patients with high-risk HER2-positive early breast cancer that the ADC followed by ...
Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic imneskibart (AU-007), today presented promising ...
Throughout October, CURE highlighted research developments and evolving treatment strategies that continue to shape cancer ...
The robust 77.8% three-month CR rate observed in the UTOPIA trial is highly encouraging and reinforces the potential of UGN-103 to deliver meaningful benefits to patients,” said Liz Barrett, President ...
Reported three-month complete response rate of 77.8% from the Phase 3 UTOPIA trial of UGN-103, consistent with ENVISION results; FDA agreed to ...
If you're an individual retail investor searching for healthcare stocks you can buy and hold for at least 20 years, here are ...
A wildflower bank in Wish Park, part of a network of banks significantly increasing the diversity of plants and wildlife in ...
Studies spanning cardiovascular, aging, and cancer biology highlight how Seer’s Proteograph® platform is enabling discovery at population scale ...
Morning routines, messy mealtimes and tiny toilets collide with classroom reality as families juggle readiness, confidence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback